Amalgamated Bank lifted its position in shares of Steris PLC (NYSE:STE) by 5.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,924 shares of the medical equipment provider’s stock after buying an additional 946 shares during the quarter. Amalgamated Bank’s holdings in Steris were worth $1,480,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jaffetilchin Investment Partners LLC acquired a new position in Steris during the fourth quarter worth about $409,000. Prudential Financial Inc. raised its stake in Steris by 14.4% during the third quarter. Prudential Financial Inc. now owns 192,686 shares of the medical equipment provider’s stock worth $17,034,000 after acquiring an additional 24,220 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in Steris by 13.2% during the third quarter. Canada Pension Plan Investment Board now owns 54,100 shares of the medical equipment provider’s stock worth $4,782,000 after acquiring an additional 6,300 shares in the last quarter. Keybank National Association OH acquired a new position in Steris during the third quarter worth about $554,000. Finally, California Public Employees Retirement System grew its holdings in shares of Steris by 7.1% during the third quarter. California Public Employees Retirement System now owns 211,344 shares of the medical equipment provider’s stock worth $18,683,000 after purchasing an additional 14,062 shares during the last quarter. 89.40% of the stock is owned by institutional investors.
In other news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the stock in a transaction on Monday, March 12th. The stock was sold at an average price of $95.50, for a total transaction of $955,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Martin Steeves sold 58,953 shares of the stock in a transaction on Monday, March 5th. The stock was sold at an average price of $91.00, for a total value of $5,364,723.00. Following the transaction, the director now owns 9,362 shares of the company’s stock, valued at approximately $851,942. The disclosure for this sale can be found here. Insiders sold a total of 78,415 shares of company stock valued at $7,178,536 in the last 90 days. Corporate insiders own 2.55% of the company’s stock.
Several brokerages recently commented on STE. Zacks Investment Research cut Steris from a “buy” rating to a “hold” rating in a report on Wednesday, March 28th. Northcoast Research set a $102.00 target price on Steris and gave the company a “buy” rating in a report on Thursday, February 8th. KeyCorp restated a “buy” rating and set a $103.00 price target on shares of Steris in a report on Thursday, February 8th. Finally, Raymond James Financial restated a “market perform” rating and set a $100.00 price target on shares of Steris in a report on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $84.80.
NYSE STE traded down $2.34 on Monday, reaching $91.02. The company had a trading volume of 406,287 shares, compared to its average volume of 372,390. The firm has a market capitalization of $7,921.42, a P/E ratio of 24.23 and a beta of 1.12. Steris PLC has a 52-week low of $69.11 and a 52-week high of $96.43. The company has a current ratio of 2.82, a quick ratio of 2.22 and a debt-to-equity ratio of 0.46.
Steris (NYSE:STE) last released its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.05. The business had revenue of $661.90 million during the quarter, compared to analyst estimates of $663.17 million. Steris had a return on equity of 11.57% and a net margin of 9.42%. Steris’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.98 EPS. sell-side analysts predict that Steris PLC will post 4.13 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th were paid a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date was Tuesday, February 27th. This is an increase from Steris’s previous quarterly dividend of $0.21. Steris’s dividend payout ratio is 32.98%.
COPYRIGHT VIOLATION WARNING: “Steris PLC (NYSE:STE) Holdings Increased by Amalgamated Bank” was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://theenterpriseleader.com/2018/04/02/amalgamated-bank-purchases-946-shares-of-steris-plc-nyseste.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.